Scienture (NASDAQ:SCNX – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.
Analyst Recommendations
This is a summary of recent recommendations for Scienture and Silo Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scienture | 1 | 0 | 1 | 0 | 2.00 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
Scienture presently has a consensus price target of $1.50, indicating a potential upside of 920.41%. Given Scienture’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Scienture is more favorable than Silo Pharma.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scienture | $430,000.00 | 14.04 | -$41.51 million | ($2.10) | -0.07 |
| Silo Pharma | $70,000.00 | 34.19 | -$4.23 million | ($4.36) | -0.35 |
Silo Pharma has lower revenue, but higher earnings than Scienture. Silo Pharma is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
5.7% of Scienture shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 19.5% of Scienture shares are held by insiders. Comparatively, 3.6% of Silo Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Scienture and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scienture | N/A | -53.51% | -42.47% |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
Volatility & Risk
Scienture has a beta of 3.35, suggesting that its share price is 235% more volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
Summary
Scienture beats Silo Pharma on 12 of the 14 factors compared between the two stocks.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
